GET DAILY SIGNALSFresenius Medical Care (FMS) Delivers Steady Q3 Revenue but Narrows Full-Year Outlook
Key Takeaways
- Fresenius Medical Care reported third quarter 2026 revenue of €4.94 billion, up 1% year over year, while organic growth was essentially flat at 0.1%.
- Net income attributable to shareholders fell 42% to €160 million, pressured by roughly €108 million in one-time costs tied to the company's revised China strategy.
- Adjusted basic earnings per share (EPS) rose slightly to €1.11, compared with €1.10 in the prior-year quarter.
- Management narrowed its full-year 2026 operating income outlook to flat-to-negative mid-single-digit growth, citing expected fourth-quarter headwinds.
- The FME25+ cost-transformation program delivered €74 million in sustainable savings during the quarter, keeping the company on track for its €250 million full-year target.
- For additional context on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
- Discover automated trading strategies powered by artificial intelligence through Trending AI Robots.
Why These Results Matter
Fresenius Medical Care stands as the world's largest provider of kidney dialysis products and services, so its quarterly performance offers a useful window into the renal-care sector overall. The latest report comes during an ongoing multi-year transformation that includes clinic consolidation, manufacturing adjustments, and the rollout of the 5008X CAREsystem dialysis machines. Reimbursement changes also played a role, as the Transitional Drug Add-on Payment Adjustment shifted from a positive to a negative influence with the phase-down of phosphate-binder payments. The key question for investors is whether operational gains can counterbalance these factors along with the costs of the China strategy update.
Breaking Down the Numbers
Group revenue rose 1% to €4,937 million from €4,885 million a year earlier, though it declined 1% at constant currency and increased just 0.1% on an organic basis. Reported operating income dropped 19% to €384 million for a 7.8% margin, while operating income excluding special items fell 5% to €545 million, yielding an 11.0% margin.
Reported net income attributable to shareholders declined 42% to €160 million, and basic EPS fell 35% to €0.61 from €0.94. Special items totaled a net negative €161 million, including about €108 million in one-time costs from the China strategy refinement covering impairment, scrappage, and termination expenses. Adjusted net income came in at €291 million versus €322 million previously, while adjusted basic EPS edged up to €1.11 from €1.10, aided by the share buyback program. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Guidance remained unchanged for broadly flat revenue growth in fiscal 2026, but the operating income range was narrowed to flat through negative mid-single-digit growth.
Market Reaction and Sentiment
Shares moved modestly lower after the release on both European and U.S. exchanges. The response highlighted a mixed picture: revenue stability and the slight lift in adjusted EPS were positive, yet the tighter operating income guidance and the size of the China-related charges tempered enthusiasm. Adjusted operating income declined 6% at constant currency, showing that inflation and reimbursement pressures continue to affect margins even with ongoing cost savings. The active buyback program, which had repurchased 3.4% of share capital by the end of September, offered some support.
Looking Ahead
Investors will focus on how the company handles the intensified fourth-quarter TDAPA headwind as phosphate-binder payments wind down. Progress with the 5008X CAREsystem rollout is another point of attention; by late September, 348 clinics had been converted, representing about 14% of the U.S. network, with roughly 9,000 machines installed and the target of 20% conversion by year-end still in view. Inflation in the Care Enablement segment and weaker patient referrals earlier in the year remain risks. On the positive side, the FME25+ program is delivering savings, and the second €1 billion share buyback reflects confidence in future cash flow. Updates on the China restructuring and the Value-Based Care segment will also be worth watching, especially around contract risk changes. From what I see, the ability to sustain margins near current levels while managing these pressures will shape the story into 2027.
Using AI Tools for Deeper Analysis
I often turn to Tickeron’s AI Screener when reviewing earnings like these to quickly compare fundamentals and technical signals across the healthcare sector. It helps surface relevant peers and patterns that might otherwise take more time to identify manually, giving a clearer view of relative positioning without replacing primary research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FMS in upward trend: 10-day moving average broke above 50-day moving average on November 02, 2026
The 10-day moving average for FMS crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FMS's RSI Oscillator exited the oversold zone, 15 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 43%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on FMS as a result. In 48 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for FMS just turned positive on October 15, 2026. Looking at past instances where FMS's MACD turned positive, the stock continued to rise in 25 of 43 cases over the following month. The odds of a continued upward trend are 58%.
Following a +2.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where FMS advanced for three days, in 194 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
FMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 59 cases where FMS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 53%.
FMS moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for FMS entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.958) is normal, around the industry mean (204.016). P/E Ratio (13.620) is within average values for comparable stocks, (19.314). Projected Growth (PEG Ratio) (0.741) is also within normal values, averaging (2.498). Dividend Yield (0.154) settles around the average of (0.094) among similar stocks. P/S Ratio (0.574) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating fairly steady price growth. FMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 78 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of renal and dialysis products
Industry HospitalNursingManagement
Advertisement